RT Journal
A1 Miller DC, Hollenbeck BK
T1 MIssing the mark on prostate-specific antigen screening
JF JAMA
JO JAMA
YR 2011
FD December 28
VO 306
IS 24
SP 2719
OP 2720
DO 10.1001/jama.2011.1879
UL http://dx.doi.org/10.1001/jama.2011.1879
AB 
The US Preventive Services Task Force recently issued a draft recommendation against prostate-specific antigen (PSA) screening for prostate cancer.1 After performing a rigorous review of the relevant empirical literature, the task force concluded with “moderate certainty” that the harms of PSA-based detection (eg, biopsy-related complications) and early intervention (eg, incontinence, erectile dysfunction) exceed the potential benefits. For this reason, the task force now proposes discouraging PSA screening among men who are free of symptoms suspicious for prostate cancer.